Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

PLUS THERAPEUTICS, Inc. - Common Stock (NQ: PSTV )

1.090 +0.100 (+10.10%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PLUS THERAPEUTICS, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
EXCLUSIVE: Cancer Firm Plus Therapeutics Licenses Diagnostic Assay To Detect Central Nervous System Cancers
Plus Therapeutics Inc (NASDAQ: PSTV) has expanded its supply agreement with Biocept Inc (NASDAQ: BIOC) by acquiring an option to exclusively license Biocept's CNSide, a cerebrospinal flu 
Via Benzinga
Plus Therapeutics Presents Exciting New Clinical Data At Top Cancer Conference
Marc Hedrick, President & CEO of Plus Therapeutics (NASDAQ: PSTV), was a guest on Benzinga’s All-Access. 
Via Benzinga
Why Maxeon Solar Technologies Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Amyris, Inc. (NASDAQ: AMRS) shares jumped 179.1% to $0.1839. Amyris shares dipped over 80% on Thursday after the company announced it filed for Chapter 11 bankruptcy. 
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Plus Therapeutics Earnings Preview
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Plus Therapeutics: Here's What You Need To Know
Via Benzinga
Earnings Scheduled For August 14, 2023
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million. 
Via Benzinga
Plus Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Plus Therapeutics: Q1 Earnings Insights
Via Benzinga
EXCLUSIVE: Plus Therapeutics Lead Candidate Shows Preliminary Safety, Efficacy In Type Of Brain Cancer
Plus Therapeutics Inc (NASDAQ: PSTV) reported data from the ReSPECT-LM study evaluating the company’s lead radiotherapeutic, rhenium (186Re) obisbemeda, for 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Recap: Plus Therapeutics Q1 Earnings
Via Benzinga
Earnings Preview For Plus Therapeutics
Via Benzinga
Plus Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Plus Therapeutics Releases Early-Cut Data From Cancer Studies For Brain Cancer Settings
Plus Therapeutics Inc (NASDAQ: PSTV) reported interim updates from the ReSPECT-GBM and ReSPECT-LM studies of rhenium (186Re) obisbemeda, for recurrent glioblastoma (rGBM)  
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Plus Therapeutics – Precision Radiology Is Proving Highly Effective At Fighting Cancer
Marc Hedrick, M.D., President and CEO of Plus Therapeutics (NASDAQ: PSTV) was recently a guest on Benzinga’s All-Access. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 32 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 32 companies reached new 52-week lows. 
Via Benzinga
This Company Is Developing Novel Treatments For Difficult To Treat CNS Cancers
Norman LaFrance, MD, CMO & Senior VP, and Melissa Moore, PhD, VP of Clinical Research for Plus Therapeutics Inc. (NASDAQ: PSTV) were recently interviewed by Benzinga. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday's session saw 286 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 74 companies achieved new lows for the year. 
Via Benzinga
Why Geron Shares Are Trading Lower By 13%; Here Are 20 Stocks Moving Premarket
Gainers Vyant Bio, Inc. (NASDAQ: VYNT) shares rose 110.4% to $1.62 in pre-market trading after the company said it has engaged LifeSci Capital as its advisor to explore strategic alternatives. 
Via Benzinga
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 116 companies set new 52-week lows. 
Via Benzinga
Why G Medical Innovations Shares Are Trading Lower By 35%; Here Are 25 Stocks Moving Premarket
Gainers EUDA Health Holdings Limited (NASDAQ: EUDA) shares rose 88.1% to $8.40 in pre-market trading after merger completed with 8i Acquisition SPAC last week. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.